IPO - AEON Biopharma, Inc.
Form Type: 424B5
Filing Date: 2025-01-07
Corporate Action: Ipo
Type: New
Accession Number: 000110465925001515
Filing Summary: AEON Biopharma, Inc. is initiating an offering of 40,000,000 Units consisting of one share of common stock and two series of Warrants, designated as Series A and Series B, each exercisable at $0.625. The Units will be priced at $0.50 each, aiming to raise approximately $20,000,000. The Series A Warrants become exercisable with stockholder approval and have a five-year expiry, while the Series B Warrants also require stockholder approval and will expire in two and a half years. The document discusses adjustments to the exercise prices based on company actions, including stock splits and additional common stock issuances at prices lower than the Warrants’ exercise price. Proceeds from the offering are intended for general corporate purposes, including paying down senior notes. AEON’s common stock trades on the NYSE American under the symbol “AEON.”
Document Link: View Document
Additional details:
Public Offering Price: $0.50
Total Proceeds Before Expenses: $20,000,000
Underwriter Discounts First 30000000 Units: $0.035
Underwriter Discounts Last 10000000 Units: $0.045
Proceeds To Company Per Unit: $0.46
Total Proceeds To Company: $18,400,000
Warrant Expiry Series A: 5 years after Warrant Stockholder Approval
Warrant Expiry Series B: 2.5 years after Warrant Stockholder Approval
Form Type: 8-K
Filing Date: 2025-01-07
Corporate Action: Ipo
Type: New
Accession Number: 000110465925001665
Filing Summary: On January 6, 2025, AEON Biopharma, Inc. entered into an underwriting agreement with Aegis Capital Corp. for a public offering. The company agreed to sell 40,000,000 Common Units, comprising one share of Common Stock and two Series of Warrants (Series A and Series B) at an exercise price of $0.625 each. The Underwriter was granted a 45-day option to purchase additional shares and Warrants. On January 7, 2025, the Underwriter exercised its option for an additional 6,000,000 Series A Warrants and 6,000,000 Series B Warrants. The offering was registered under Form S-3 and the company received approximately $18.3 million in net proceeds after expenses. The funds are intended for general corporate purposes, including working capital. The company also issued press releases on January 6 and 7, 2025, announcing the pricing and closing of the offering respectively.
Document Link: View Document
Additional details:
Date Of Report: 2025-01-06
Underwriter Name: Aegis Capital Corp.
Number Of Common Units: 40000000
Exercise Price Series A Warrant: 0.625
Exercise Price Series B Warrant: 0.625
Number Of Series A Warrants Exercised: 6000000
Number Of Series B Warrants Exercised: 6000000
Net Proceeds: 18.3 million
Offering Expenses: included
Total Shares Outstanding: 79970693
Comments
No comments yet. Be the first to comment!